Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Over 152 weeks, patients stably maintained and extended their regrowth across scalp, eyebrows, and eyelashes with continued baricitinib treatment. There were no new safety signals.
Authors
- Susan Ball (ORCID: https://orcid.org/0000-0001-9866-6721)
- Manabu Ohyama (ORCID: https://orcid.org/0000-0002-2662-5717)
- Jill Kolodsick
- Rodney Sinclair (ORCID: https://orcid.org/0000-0001-6751-1428)
- Chunyuan Liu (ORCID: https://orcid.org/0000-0002-2682-4441)
- Maryanne M. Senna (ORCID: https://orcid.org/0000-0002-7813-520X)
- Najwa Somani
- Chiara Chiasserini
- Guanglei Yu (ORCID: https://orcid.org/0000-0003-0954-3397)
- Arash Mostaghimi (ORCID: https://orcid.org/0000-0002-6084-5617)
- Brett King
Institutions
- Brigham and Women's Hospital (US)
- Lahey Hospital and Medical Center (US)
- Eli Lilly (United States) (US)
- Kyorin University (JP)
- Lahey Medical Center (US)
- Sinclair Dermatology (AU)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.jaad.2025.11.064
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00